Investigations into 5-HT2A signaling mechanisms of psychedelic drugs for the treatment of stimulant use disorder
Project Number1R01DA061433-01
Contact PI/Project LeaderMCCORVY, JOHN D Other PIs
Awardee OrganizationMEDICAL COLLEGE OF WISCONSIN
Description
Abstract Text
PROJECT SUMMARY
Stimulant use disorders and overdose deaths resulting from methamphetamine use are on the rise.
Psychedelics, such as psilocybin, show therapeutic potential and efficacy against anxiety, depression,
alcoholism, and nicotine dependence, after administration of a single dose, but serotonergic psychedelics
exhibit polypharmacology and are not selective for the serotonin 5-HT2A receptor, which is necessary for
psychoactive effects. In this proposal we aim to investigate the role of 5-HT2A receptor signaling in
methamphetamine (METH) self-administration, neuroplasticity in vitro and in vivo, and on METH-induced
amotivation. These innovative studies utilize several novel and recently identified 5-HT2A selective tool
compounds with a range of G protein and β-arrestin recruitment efficacies designed to address the signaling
mechanisms involved in each of the following aims. In aim 1, we will determine the role of 5-HT2 receptors and
signaling pathways that lead to the suppression of reinforcing effects in a METH self-administration model. In
aim 2, we will examine the role of neuroplasticity in the attenuation of METH effects induced by psychedelics
and 5-HT2A selective agonists. In aim 3, we will determine the contribution of 5-HT2A and 5-HT2C receptors
toward attenuation of METH-induced amotivation using progressive ratio breakpoint task (PRBT) and
probabilistic reversal learning task (PRLT). Together, these studies will identify serotonin receptor signaling
profiles as a clear mechanism for psychedelic-induced efficacy for stimulant use disorders, with the potential to
identify neuroplastic and non-psychedelic signaling mechanisms for more effective treatments for drugs of
misuse.
1
Public Health Relevance Statement
PROJECT NARRATIVE
Stimulant use disorders and overdose deaths are surging nationwide, and evidence indicates that psychedelics
(5-HT2A agonists), such as psilocybin, reduce stimulant use and increase abstinence to a greater degree than
psychotherapy alone. We propose to utilize novel selective 5-HT2A tool compounds with full, partial, and biased
agonism to investigate the effects on attenuation of methamphetamine self-administration, neuroplasticity, and
amotivation. The goal of this proposal is to identify 5-HT2A signaling mechanisms critical for treating drug
misuse.
1
No Sub Projects information available for 1R01DA061433-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01DA061433-01
Patents
No Patents information available for 1R01DA061433-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01DA061433-01
Clinical Studies
No Clinical Studies information available for 1R01DA061433-01
News and More
Related News Releases
No news release information available for 1R01DA061433-01
History
No Historical information available for 1R01DA061433-01
Similar Projects
No Similar Projects information available for 1R01DA061433-01